CalciMedica Inc
Company Profile
Business description
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.
Contact
505 Coast Boulevard South
Suite 307
La JollaCA92037
USAT: +1 858 952-5500
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
15
Stocks News & Analysis
stocks
Perplexing buyback from overvalued ASX share
stocks
Most popular shares in SMSFs
stocks
Will China strong arm BHP into lower iron ore prices?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,183.30 | 36.30 | -0.39% |
| CAC 40 | 7,956.15 | 38.15 | 0.48% |
| DAX 40 | 24,367.80 | 126.34 | 0.52% |
| Dow JONES (US) | 45,479.60 | 878.82 | -1.90% |
| FTSE 100 | 9,434.16 | 6.69 | 0.07% |
| HKSE | 25,889.48 | 400.84 | -1.52% |
| NASDAQ | 22,204.43 | 820.20 | -3.56% |
| Nikkei 225 | 48,088.80 | 491.64 | -1.01% |
| NZX 50 Index | 13,351.92 | 115.34 | -0.86% |
| S&P 500 | 6,552.51 | 182.60 | -2.71% |
| S&P/ASX 200 | 8,882.80 | 36.30 | -0.41% |
| SSE Composite Index | 3,889.50 | 7.53 | -0.19% |